Malignant Myeloma in a Patient After Treatment for Osteoporosis with Teriparatide; a Rare Coincidence

@article{Forslund2008MalignantMI,
  title={Malignant Myeloma in a Patient After Treatment for Osteoporosis with Teriparatide; a Rare Coincidence},
  author={Terje Forslund and Anna-Mari Koski and A. Koistinen and A. Siki{\"o}},
  journal={Clinical Medicine. Case Reports},
  year={2008},
  volume={1},
  pages={119 - 122}
}
  • Terje Forslund, Anna-Mari Koski, +1 author A. Sikiö
  • Published 2008
  • Medicine
  • Clinical Medicine. Case Reports
  • A breakthrough in understanding of mechanisms of bone structure regulation has brought about the introduction of the new synthetic recombinant human parathyroid hormone 1–34 (PTH1-34; Teriparatide) in the treatment of osteoporosis. These mechanisms, involving the RANKL, RANK, and osteoprotegerin system, are also known to be involved in malignant myeloma (MM) and tumor and bone metastasis development. We report a case in which MM was found after treatment of osteoporosis with teriparatide. We… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 27 REFERENCES
    Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation
    • 4,962
    OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis
    • 3,036
    Minireview: the OPG/RANKL/RANK system.
    • 1,306
    • Highly Influential
    • PDF
    Biology of osteoclast activation in cancer.
    • 300
    • Highly Influential